Deafness

Children with hereditary deafness receive back their hearing ability through gene therapy

By Editor's Desk
28 January 2024

new developments in gene therapy research today

new developments in gene therapy research today

Of the six treated youngsters, five showed improvement in their hearing.

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

Regulatory Approval Healthcare & Pharmaceuticals News

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

18 July 202617 July 2026

Regulatory Intelligence Desk

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

Regulatory Approval Healthcare & Pharmaceuticals News

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

17 July 202617 July 2026

Regulatory Intelligence Desk

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Merger & Acquisitions Business Healthcare & Pharmaceuticals

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

16 July 202616 July 2026

BiotechReality Business Intelligence Desk

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Business Healthcare & Pharmaceuticals News

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

15 July 202616 July 2026

BiotechReality Business Intelligence Desk

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

15 July 202615 July 2026

Regulatory Intelligence Desk

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

Merger & Acquisitions Healthcare & Pharmaceuticals News Oncology

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

14 July 202615 July 2026

BiotechReality Business Intelligence Desk